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license (http://creativecommons.org/licenses/by/4.0/).A ntineutrophil cytoplasmic antibody (ANCA)associated vasculitis is a multisystem autoimmune
disease that often involves the lungs. It can be serious
and sometimes fatal, and requires prompt recognition
and treatment. Cyclophosphamide is a well-established
alkylating agent that is widely used in the treatment
of ANCA vasculitis. The most common side effects of
cyclophosphamide are infection and the risk of
malignancy.CASE PRESENTATION
A 61-year-old man, a lifelong smoker, was investigated
in the respiratory outpatient clinic for progressive
breathlessness. Pulmonary function tests at the time
revealed a forced expiratory volume in 1 second (FEV1)
of 2.84 L (predicted 3.2) and a forced vital capacity (FVC)
of 4.9 L (predicted 5.1) with an FEV1/VC of 0.58. Based
on these values, he was diagnosed with chronic
obstructive pulmonary disease. His breathlessness
continued to worsen and was associated with reduced
exercise tolerance. As a result he underwent a high-
resolution computed tomography (HRCT) scan of the
lungs 2 months later. This showed extensive emphy-
sema and bi-basal peripheral–ground-glass changes with
possible honeycomb cyst formation (Figure 1a). Serum
creatinine was normal at this time. The patient re-
presented 2 months later with symptoms of lethargy,
worsening breathlessness, and numbness affecting his
left foot.
Physical examination revealed bi-basal ﬁne expi-
ratory crackles in the lungs alongside a mononeuritis
multiplex. Renal function was severely impaired with
a serum creatinine of 13.01 mg/dl (normal range 0.60–
1.10) and C-reactive protein (CRP) was elevated at 93
mg/dl (normal range 0–5). Myeloperoxidase anti-
neutrophil cytoplasmic antibody (ANCA) titers were
raised at >100 IU/ml (normal range 0–5). The patientInternational Reports (2019) -, -–-went on to have a renal biopsy. This showed an active
segmental and necrotizing glomerulonephritis with
evidence of signiﬁcant tubular atrophy and intersti-
tial ﬁbrosis. Overall, the clinical diagnosis was of an
ANCA-associated systemic vasculitis, most in keeping
with microscopic polyangiitis.
Despite the signiﬁcant chronic renal damage, the
patient was treated with a combination of prednisone (1
mg/kg/d), plasmapheresis, and i.v. cyclophosphamide in
addition to hemodialysis. His clinical condition
improved signiﬁcantly, in particular his shortness of
breath. However, he remained dialysis dependent. He
was discharged home with a plan to continue outpatient
treatment with i.v. cyclophosphamide alongside a
reduction of his prednisone dose. A repeat HRCT before
discharge showed no new changes compared to the
HRCT from a few months earlier.
The patient re-presented 6 weeks later with marked
dyspnea. Despite 14.5 L of ﬂuid removal on hemodi-
alysis and treatment with broad-spectrum antibiotics,
he remained dyspneic. Results of sputum and blood
cultures as well as respiratory viral swabs were nega-
tive. Results of investigations for Pneumocystis jirovecii
pneumonia were also negative. Diffuse alveolar hem-
orrhage was considered, although imaging was not
consistent with this, hemoglobin was stable, and there
was no externalization of blood. The patient was not ﬁt
to undergo bronchoscopy. An HRCT scan of the lungs
was reported as showing severe centrilobar and para-
septal emphysema with super-added inﬂammatory
changes (Figure 1b), signiﬁcantly worse compared to a
scan 2 months earlier. The patient had received 2 doses
of i.v. cyclophosphamide, and it was believed that this
was implicated. Following its withdrawal, the patient’s
symptoms and exercise tolerance gradually improved.
An HRCT 3 months later showed resolution of the lung
changes seen on CT immediately before cyclophos-
phamide cessation (Figure 1c). The patient was1
Figure 1. (a) Initial computed tomogram with mild changes, notably extensive emphysema, and bi-basal peripheral–ground-glass changes. (b)
Computed tomogram from 4 months later (after initiation of cyclophosphamide), with severe centrilobar and paraseptal emphysema with new
inﬂammatory changes. (c) Improvement in the changes seen in (b), 3 months after cyclophosphamide withdrawal.
NEPHROLOGY ROUNDS D Pugh et al.: Cyclophosphamide-Induced Lung Injurydiagnosed with cyclophosphamide-induced acute
pneumonitis. His prednisone dose was increased tran-
siently following withdrawal of cyclophosphamide.
DISCUSSION
Cyclophosphamide is an established alkylating agent that
is widely used in the treatment of ANCA-associated
vasculitis and in hematological malignancies as part of
a chemotherapy regimen. Its most commonly recognized
side effects are those of infection and the long-term risk
of malignancy. Pulmonary side effects are rare (<1%)
and are dose related.1 They manifest as either an early-
onset pneumonitis, with patients presenting with
cough and dyspnea within 6 months of starting treat-
ment, or as a late ﬁbrosis with gradual worsening dys-
pnea and a nonproductive cough (Table 1).2
The diagnosis of cyclophosphamide-related lung
injury is made clinically on the basis of symptoms, his-
tory of cyclophosphamide use, compatible ﬁndings on
chest imaging studies, and the absence of an alternative
diagnosis. Early drug toxicity may respond to discon-
tinuation of cyclophosphamide alongside glucocorticoids,
whereas late toxicity is usually untreatable. It is unclear
whether a higher total dose of cyclophosphamide is a risk
factor for lung toxicity, as affected patients have received
doses ranging from 150 mg to 81 g.2,3 As demonstratedTable 1. Teaching points related to the case
1. Cyclophosphamide, a commonly used alkylating agent for the treatment of
ANCA-associated vasculitis, can cause direct lung toxicity
2. Lung damage can manifest as early-onset pneumonitis (likely reversible) or late-onset
lung ﬁbrosis (usually irreversible)
3. When considering patients undergoing hemodialysis who present with symptoms and
signs of cyclophosphamide-associated lung injury, it is important to ﬁrst exclude
pulmonary infection and edema
4. In patients with a pneumonitis-type picture, as presented here, withdrawal of
cyclophosphamide can lead to resolution of symptoms and radiographic evidence of
disease
ANCA, antineutrophil cytoplasmic antibody.
2here, HRCT may be a better imaging modality than plain
chest X-ray for detecting these changes (serial chest X-
rays for the patient described here are shown in
Figure 2).
The importance of recognizing the pulmonary
toxicity associated with cyclophosphamide is under-
scored by the fact that the prevalence rates of ANCA-
associated vasculitis, for which cyclophosphamide is
the main therapeutic agent, are increasing, as are the
global rates of cancer, another indication for treatment
with this agent.4,5 Furthermore, the sales of cyclophos-
phamide in the United States alone for the year ending
September 2014 amounted tow$420 million according
to IMS Health. There have been few data published over
the past 20 years detailing the important pulmonary
toxicity associated with the drug described here. When
considering cyclophosphamide-related lung injury in
those patients receivingmaintenance hemodialysis, ﬂuid
overload should ﬁrst be excluded.
PATIENT PERSPECTIVE
Diagnosis and Initial Treatment
“I remember feeling constantly tired and
exhausted. I could hardly walk the length of my
front room without feeling breathless. The treatment
worked really well for my breathing. But of
course, what was really beginning to worry me at
that time was being started on dialysis.”
Re-admission
“Life was much more difﬁcult after I made it home
the ﬁrst time. The diagnosis began to sink in, I
still had to travel to the hospital three times a week
for dialysis, and I came to rely on those around me
for a lot of things that I could do myself before, like
shopping and cooking.Kidney International Reports (2019) -, -–-
Figure 2. (a) X-ray taken before cyclophosphamide treatment. (b) X-ray taken during treatment. (c) X-ray taken 2 months after cyclophos-
phamide was discontinued. The pretreatment X-ray was reported as showing a largely peripheral and basal pattern of ﬁbrosis, which then
improved signiﬁcantly following drug withdrawal.
D Pugh et al.: Cyclophosphamide-Induced Lung Injury NEPHROLOGY ROUNDSAfter a while, though, I noticed I was becoming
more short of breath and struggling whenever I left
the house. It got to the stage where I could hardly
speak without feeling short of breath. That’s when I
decided enough was enough and I needed help again.
Things have taken a lot longer to get better this time,
but it still feels like things are going in the right
direction.”
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